Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 874
Filtrar
1.
Rev Soc Bras Med Trop ; 54: e0514-2020, 2021.
Artigo em Inglês | MEDLINE | ID: mdl-33759920

RESUMO

A 31-year-old male patient developed an ulcer on the glans penis that evolved for three months without healing. We diagnosed it as leishmaniasis using polymerase chain reaction. No immunosuppression or associated diseases were observed. The patient was treated with meglumine antimoniate that cured the lesion in a month post-treatment. Here, we report this case of cutaneous leishmaniasis lesion at the unusual location of glans penis in an immunocompetent individual. The lesion likely developed due to the bite of a vector, highlighting the need for considering cutaneous leishmaniasis among differential diagnosis of sexually transmitted diseases in areas endemic for leishmaniasis.


Assuntos
Antiprotozoários , Leishmaniose Cutânea , Compostos Organometálicos , Adulto , Antiprotozoários/uso terapêutico , Brasil , Genitália , Humanos , Leishmaniose Cutânea/diagnóstico , Leishmaniose Cutânea/tratamento farmacológico , Masculino , Meglumina/uso terapêutico , Antimoniato de Meglumina/uso terapêutico , Compostos Organometálicos/uso terapêutico , Reação em Cadeia da Polimerase
2.
Artigo em Russo | MEDLINE | ID: mdl-33340298

RESUMO

OBJECTIVE: To study the efficacy of reamberin in treatment of epilepsy in children and to evaluate its effect on the cognitive functions. MATERIAL AND METHODS: The study included 51 patients with epilepsy aged 7 to 15 years. The children were divided into four groups depending on the prescribed treatment. The first study group (n=16) received intravenous reamberin once daily for 5 days in addition to carbamazepine. The second group (n=15) received intravenous reamberin once daily for 5 days in addition to valproic acid. Two comparison groups (10 patients each) received only carbamazepine or only valproic acid, respectively. Cognitive functions were assessed at admission and on the 6th day of treatment using Schulte tables (10 words). RESULTS AND CONCLUSION: Reamberin significantly increases the work efficiency by 19-21%, and workability degree by 8-12% compared with the patients of the control groups. An analysis of the effect of succinate-containing drug on auditory memory has shown that the volumes of short-term memory and long-term memory are by 1.8 times and 1.3 times, respectively, higher than those in the control groups. Thus, the addition of reamberin into the treatment of children with epilepsy should be considered clinically reasonable, and promising.


Assuntos
Epilepsia , Succinatos , Adolescente , Anticonvulsivantes/uso terapêutico , Criança , Cognição , Epilepsia/tratamento farmacológico , Humanos , Meglumina/análogos & derivados , Meglumina/uso terapêutico , Succinatos/uso terapêutico
3.
Khirurgiia (Mosk) ; (2): 95-99, 2020.
Artigo em Russo | MEDLINE | ID: mdl-32105263

RESUMO

A 51-year-old severely burned woman had hospitalized at the Clinic of Thermal Injuries of the S.M. Kirov Military Medical Academy with a diagnosis: flame burn in a surface area of 40% (11%)/II-III b degrees of head, neck, trunk, limbs. Inhalation injury of moderate severity. The infusion drug of the combined action reamberin, which has a volemic and antihypoxic effect, had added to the complex antishock therapy. The presented clinical observation demonstrates the favorable course of burn shock: stopping of burn shock 28 hours after injury.


Assuntos
Queimaduras , Meglumina/análogos & derivados , Militares , Choque , Succinatos , Queimaduras/complicações , Feminino , Hidratação , Humanos , Meglumina/uso terapêutico , Pessoa de Meia-Idade , Choque/etiologia , Choque/terapia , Succinatos/uso terapêutico
4.
Farm. comunitarios (Internet) ; 11(3): 13-18, sept. 2019. graf, tab
Artigo em Espanhol | IBECS | ID: ibc-186879

RESUMO

Antecedentes: la leishmaniosis es una zoonosis vectorial que en humanos inmunodeprimidos presenta forma sistémica, estando la forma cutánea infradiagnosticada. El tratamiento para el portador tiene un elevado coste. Propietarios y centros de adopciones carecen de recursos, pero no tratar o prevenir implica tener a un portador de una zoonosis disponible para el vector. Por ello existe una tendencia a la sustitución por la presentación de humana por los agentes implicados, adelantándose a los responsables en materia de salud pública. Objetivos: conocer la incidencia de animales portadores, la proporción de medicamentos prescritos por los veterinarios, las tendencias de búsqueda en internet de medicamentos para prevención y el tratamiento. Metodología: análisis serológico por técnica de inmunoensayo de 255 perros, aplicación de precios de mercado a los resultados, encuesta sobre la prescripción de veterinarios clínicos y análisis de tendencias de búsqueda de información en internet entre usuarios. Resultados: 38 perros resultaron ser portadores inaparentes (infectados, pero no enfermos) y 28 portadores enfermos. El resto son no portadores. Se obtuvo una diferencia de precio de más del 50 % en el tratamiento entre medicamentos de humana o genéricos y el de veterinaria. En la prevención la diferencia es 11 veces el precio veterinario frente al de humana. Los veterinarios prescriben correctamente, pero informan de otras opciones más baratas y la tendencia de búsqueda en internet está orientada al precio y a la sustitución. Conclusión: el precio es la principal causa de sustitución del medicamento prescrito y la legislación no está atendiendo la relevancia de esta zoonosis. Las autoridades sanitarias han de valorar las necesidades reales en materia de salud pública


Background: Leishmaniasis is a vectorial zoonosis with systemic presentation in immunosuppressed humans, the cutaneous form is underdiagnosed. A lot of owners and Rescue kennels can not pay the treatment because it is very expensive, but not treating or not preventing is dangerous for Public Health. Therefore, there is a tendency to replace the veterinary drug by the human drug form, ahead of those responsible for Public Health. Objectives: To know the disease carrier animals, the prescription tendencies of the veterinarians, the tendencies of search in Internet of drugs for prevention and treatment. Methods: Blood test of 255 animals, application of market prices to the results, survey on the prescription of clinical veterinarians and analysis of Internet search trends among users. Results: 38 dogs were founded inapparent carriers (infected, but not ill) and 28 sick carriers. The rest were non-carriers. A price difference of more than 50 % was obtained in the treatment between human or generic drugs and that of veterinary medicine. About the prevention, the difference is 11 times the veterinary price compared to that of humans. Veterinarians prescribe correctly but report other cheaper options and the search trend on the internet is price and replacement oriented. Conclusion: The price is the main cause of substitution and the legislation is not agree the relevance of this zoonosis. The health authorities must assess the real needs in terms of Public Health


Assuntos
Animais , Cães , Leishmania/efeitos dos fármacos , Leishmaniose/tratamento farmacológico , Leishmaniose/veterinária , Farmácias , Substituição de Medicamentos/tendências , Drogas Veterinárias , Meglumina/uso terapêutico , Antimoniato de Meglumina/uso terapêutico , Antiprotozoários
5.
Khirurgiia (Mosk) ; (8): 91-94, 2019.
Artigo em Russo | MEDLINE | ID: mdl-31464282

RESUMO

A successful administration of NPWT-therapy combined with Reamberin infusion for gastroenterostomy failure after stomach resection is reported in the article. It was noted that antioxidant/antihypoxic drug Reamberin combined with NPWT-therapy has a positive metabolic effect and results more active and rapid healing of the wounds. The absence of adverse effects of the drug allows us to recommend its inclusion into complex treatment of patients with this pathology.


Assuntos
Antioxidantes/uso terapêutico , Gastrectomia/métodos , Gastroenterostomia/efeitos adversos , Fármacos Gastrointestinais/uso terapêutico , Meglumina/análogos & derivados , Tratamento de Ferimentos com Pressão Negativa , Estômago/cirurgia , Succinatos/uso terapêutico , Gastrectomia/efeitos adversos , Humanos , Meglumina/uso terapêutico , Cicatrização/efeitos dos fármacos
6.
Zh Nevrol Psikhiatr Im S S Korsakova ; 119(11. Vyp. 2): 74-79, 2019.
Artigo em Russo | MEDLINE | ID: mdl-32207735

RESUMO

AIM: To study the efficacy of reamberin in treatment of epilepsy in children and to evaluate its effect on the antioxidant status. MATERIAL AND METHODS: The antioxidant activity of reamberin was investigated in children with epilepsy: 16 patients received intravenous reamberin once daily for 5 days in addition to carbamazepine. Patients of the control group (n=15) received only carbamazepine. The efficacy of the drug was evaluated by the levels of lipid hydroperoxides, conjugated dienes, and malondialdehyde and by the activity of the main components of the antioxidant system (ceruloplasmin, vitamin E, catalase) in the blood of patients. RESULTS AND CONCLUSION: Reamberin significantly reduces the plasma levels of lipid hydroperoxides by 16%, conjugated dienes by 12%, and malondialdehyde by 25% compared with the patients of the control group. An analysis of the effect of succinate-containing drugs on the activity of the antioxidant system components has shown that blood concentrations of ceruloplasmin, vitamin E and catalase are by 35, 14% and 15%, respectively, higher than those in the control group. Thus, the addition of reamberin into the treatment of children with epilepsy should be considered pathogenetically justified, clinically reasonable, and promising.


Assuntos
Antioxidantes/metabolismo , Epilepsia/tratamento farmacológico , Epilepsia/metabolismo , Meglumina/análogos & derivados , Succinatos/farmacologia , Succinatos/uso terapêutico , Carbamazepina/farmacologia , Carbamazepina/uso terapêutico , Catalase/sangue , Ceruloplasmina/metabolismo , Criança , Humanos , Peróxidos Lipídicos/sangue , Malondialdeído/sangue , Meglumina/administração & dosagem , Meglumina/farmacologia , Meglumina/uso terapêutico , Succinatos/administração & dosagem , Vitamina E/sangue
8.
Khirurgiia (Mosk) ; (9): 68-73, 2018.
Artigo em Russo | MEDLINE | ID: mdl-30307425

RESUMO

The aim of the study was to study the effectiveness of pathogenetic correction of the metabolism with the inclusion of reamberin (1.5% sodium meglumine succinate solution) in patients with lesions of large segments of the lower limbs. In connection with the task, the efficiency pathogenetic correction of metabolism in 211 patients with diaphyseal hip and shin bones fractures had been analyzed. Patients were divided into the main and control groups. In the main group (86 patients), intravenous infusions of reamberin were administered intravenously at a rate of 1 ml/min at a rate of 10 ml/kg of body weight 1 time per day, a course of 10 days. Patients in the comparison group (125 patients) received an infusion therapy with isotonic solution. The parameters of functional activity and peripheral blood dates had been analyzed. The analysis showed that the use of antihypoxants in the perioperative period provides an earlier recovery of the physical component of quality of life in patients with lesions of large segments of the lower limbs that have undergone stably - functional osteosynthesis according to the principles of Damage control.


Assuntos
Antioxidantes/uso terapêutico , Fraturas do Quadril/tratamento farmacológico , Meglumina/análogos & derivados , Succinatos/uso terapêutico , Fraturas da Tíbia/tratamento farmacológico , Antioxidantes/administração & dosagem , Fixação Interna de Fraturas , Fraturas do Quadril/metabolismo , Fraturas do Quadril/cirurgia , Humanos , Infusões Intravenosas , Meglumina/administração & dosagem , Meglumina/uso terapêutico , Período Perioperatório , Recuperação de Função Fisiológica , Succinatos/administração & dosagem , Fraturas da Tíbia/metabolismo , Fraturas da Tíbia/cirurgia , Resultado do Tratamento
9.
Brasília; CONITEC; out. 2018. tab.
Não convencional em Português | BRISA/RedTESA | ID: biblio-997775

RESUMO

CONTEXTO: A leishmaniose tegumentar (LT) é uma doença infecciosa e não contagiosa, que acomete pele e mucosas, e é causada por protozoários do gênero Leshmania. A doença apresenta baixa letalidade, mas pode causar graves deformidades que impactam na autoestima dos pacientes. É considerada uma doença negligenciada por acometer principalmente populações de baixa renda e permanece como relevante problema de saúde pública, com consideráveis taxas de incidência e prevalência no País. Os medicamentos atualmente preconizados pelo Ministério da Saúde para o tratamento da LT são todos de uso sistêmico e apresentam um potencial hepato, cardio e nefrotóxico, sendo o antimoniato de meglumina, o tratamento de primeira escolha. A maior parte dos casos de LT ocorre em áreas de difícil acesso, o que dificulta tanto a aplicação parenteral da droga, como o monitoramento de seus efeitos colaterais. A miltefosina é um medicamento de uso oral e eficaz no tratamento da LT, mas ainda não é disponibilizada no SUS. A disponibilização de um medicamento de uso oral e efetivo contra a leishmaniose aumentaria a adesão ao tratamento nas áreas mais pobres e remotas do Brasil. TECNOLOGIA: Miltefosina. PERGUNTA: O uso da miltefosina é eficaz e seguro no tratamento da leishmaniose tegumentar quando comparado ao uso do medicamento recomendado como primeira linha de tratamento pelo Ministério da Saúde, o antimoniato de meglumina? EVIDÊNCIAS CIENTÍFICAS: O Parecer Técnico Científico (PTC) da Fiocruz "Miltefosina para tratamento de leishmaniose tegumentar americana: Evidências de eficácia e segurança" foi utilizado como base das evidências científicas. Na busca realizada nesse PTC, foram selecionados 6 ensaios clínicos randomizados comparando a miltefosina via oral com o antimoniato de meglumina via parenteral. Os estudos mostraram taxas similares de cura em 6 meses com os 2 medicamentos e eventos adversos de menor gravidade com a miltefosina. AVALIAÇÃO DE IMPACTO ORÇAMENTÁRIO: Estima-se que impacto orçamentário anual com a incorporação da miltefoseina varie de R$ 561.863,89 a R$ 2.809.319,45, no primeiro ano, e de R$ 8.427.958,35 a R$ 19.665.236,16, ao longo dos próximos cinco anos. O cálculo do impacto orçamentário não levou em conta os custos que seriam economizados com a incorporação da miltefosina: custos diretos, relacionados à administração parenteral dos medicamentos, e os indiretos, relacionados ao deslocamento diário do paciente, sozinho ou acompanhado de cuidadores ou outros membros da família, de sua residência até uma unidade de saúde para receber a administração parenteral dos medicamentos. Como a maioria desses pacientes residem em áreas rurais com difícil acesso aos serviços de saúde, esse deslocamento resulta em perda de trabalho. RECOMENDAÇÃO PRELIMINAR: A CONITEC, em 10/11/2016 recomendou a incorporação no SUS de miltefosina para o tratamento de pacientes com leishmaniose tegumentar. CONSULTA PÚBLICA: O tema foi colocado em consulta pública nº 40, realizada entre os dias 30/11/16 a 19/12/2016. Foram recebidas 06 contribuições de cunho técnico-científico e 3 contribuições de experiência ou opinião. Foram feitas alterações de texto e nenhuma argumentação foi considerada suficiente para alterar a recomendação preliminar. RECOMENDAÇÃO FINAL: Os membros da CONITEC em 09/05/2018 deliberaram, por unanimidade, por recomendar a incorporação no SUS de miltefosina para o tratamento de leishmaniose tegumentar em primeira linha de tratamento. DECISÃO: Incorporar a miltefosina para o tratamento da leishmaniose tegumentar em primeira linha de tratamento, no âmbito do Sistema Único de Saúde - SUS. Dada pela Portaria nº 60 de 31 de outubro de 2018, publicada no Diário Oficial da União nº 210, de 31 de outubro de 2018, seção 1, página 40.


Assuntos
Humanos , Fator de Ativação de Plaquetas/análogos & derivados , Leishmaniose Tegumentar Difusa/tratamento farmacológico , Meglumina/uso terapêutico , Avaliação da Tecnologia Biomédica , Avaliação em Saúde/economia , Sistema Único de Saúde , Brasil , Análise Custo-Benefício/economia
10.
Parasitol Res ; 117(9): 2881-2893, 2018 Sep.
Artigo em Inglês | MEDLINE | ID: mdl-29943317

RESUMO

Strains of the same Leishmania parasite species, isolated from different host organisms, may exhibit unique infection profiles and induce a change in the expression of microRNAs among host macrophages and in model host mice. MicroRNAs (MiR) are endogenous molecules of about 22 nucleotides that are involved in many regulatory processes, including the vertebrate host immune response. In this respect, the infectivity and susceptibility to antimonials of two L. infantum strains, BH46, isolated from human, and OP46, isolated from symptomatic dog, were characterized in J774 macrophages and BALB/c mice. Parasite burden was assessed in the liver, spleen, and bone marrow using the serial limiting dilution technique. A higher parasite burden was observed in the spleen and bone marrow of animals infected with OP46 compared to BH46 strain. Our results also showed that OP46 was less susceptible to the antimonials. In addition, miR-122 and miR-155 expression was evaluated in the liver and J774 macrophages, and in spleens from infected animals, respectively. An increase was observed in the expression of miR-155 in J774 macrophages infected with both strains compared to uninfected cells, with a higher expression in cells infected with OP46. However, no difference in the expression of miR-122 and miR-155 was observed in the infected animals. Thus, this study shows that OP46 was more infective for mice, it caused a higher increase in miR-155 expression in infected macrophages and was less susceptible to the antimonials evaluated. These data suggest that alteration in miR-155 level likely plays a role in regulating the response to L. infantum.


Assuntos
Tartarato de Antimônio e Potássio/uso terapêutico , Antiparasitários/uso terapêutico , Leishmania infantum/efeitos dos fármacos , Leishmaniose Visceral/tratamento farmacológico , Meglumina/uso terapêutico , MicroRNAs/biossíntese , Compostos Organometálicos/uso terapêutico , Animais , Medula Óssea/parasitologia , Modelos Animais de Doenças , Cães , Feminino , Perfilação da Expressão Gênica , Humanos , Leishmania infantum/genética , Leishmania infantum/isolamento & purificação , Leishmaniose Visceral/parasitologia , Fígado/parasitologia , Macrófagos/parasitologia , Antimoniato de Meglumina , Camundongos , Camundongos Endogâmicos BALB C , MicroRNAs/genética , Carga Parasitária , Baço/parasitologia
11.
Biomed Pharmacother ; 103: 1609-1616, 2018 Jul.
Artigo em Inglês | MEDLINE | ID: mdl-29864949

RESUMO

Visceral leishmaniasis (VL) is a fatal parasitic disease caused by the protozoan Leishmania spp. Meglumine antimoniate (MA) is the main treatment and has demonstrated a promising efficacy in a VL-model when encapsulated into negatively charged liposomes. Considering the current concept for the evaluation of pharmacokinetic parameters at early phases of drug discovery, we developed a formulation of MA-encapsulated into phosphatidylserine liposomes (MA-LP) and analyzed the in vitro antileishmanial activity, physicochemical properties, and pharmacokinetic profile in a mice model. The liposomal formulation had an internal mean diameter of 114 nm and a high stability in plasma. MA-LP was 23-fold more in vitro effective against Leishmania infantum-infected macrophages than the free drug, with a selectivity index higher than 220. The pharmacokinetic studies demonstrated that the liposomes increased the uptake of the drug by the liver and spleen and promoted sustained levels. MA-LP was first eliminated through renal excretion, followed by biliary excretion. In the blood, MA-LP followed a biexponential open model. This work emphasizes the importance of liposomes as potential drug delivery systems for visceral leishmaniasis.


Assuntos
Leishmaniose Visceral/tratamento farmacológico , Meglumina/farmacocinética , Meglumina/uso terapêutico , Compostos Organometálicos/farmacocinética , Compostos Organometálicos/uso terapêutico , Fosfatidilserinas/química , Animais , Antiprotozoários/farmacologia , Antiprotozoários/uso terapêutico , Morte Celular/efeitos dos fármacos , Modelos Animais de Doenças , Composição de Medicamentos , Liberação Controlada de Fármacos , Feminino , Leishmaniose Visceral/sangue , Leishmaniose Visceral/patologia , Lipossomos , Meglumina/sangue , Antimoniato de Meglumina , Camundongos Endogâmicos BALB C , Compostos Organometálicos/sangue , Distribuição Tecidual/efeitos dos fármacos
12.
Paediatr Int Child Health ; 38(3): 203-208, 2018 08.
Artigo em Inglês | MEDLINE | ID: mdl-29790825

RESUMO

BACKGROUND: Visceral leishmaniasis (VL) is endemic to the Mediterranean basin. In children, VL often presents with non-specific symptoms and can be life-threatening without proper treatment. AIM: To describe the epidemiological and clinical features of pediatric VL in children in Alicante, Spain. METHODS: The study included all paediatric (<15 years) cases admitted to three hospitals in the province of Alicante from May 1992 to May 2015 with diagnosis of VL (detection was either by anti-Leishmania antibodies in serology or Leishmania in blood and/or bone marrow aspirates). RESULTS: There were 38 cases of pediatric VL (18 aged <24 months, 15 aged 24-59 months and 5 aged ≥5 years). The main symptoms were fever (97.4%), followed by pallor (75.0%) and loss of appetite (46.4%). Eighty-seven per cent of patients were anaemic (haemoglobin < 9 g/dL), 73.7% had neutropenia and 68.4% had thrombocytopenia. Before 2004, 92.3% of patients were treated with meglumine antimoniate (MA) and 7.7% with liposomal amphotericin B (LAmB); after 2004, 84% were treated with LAmB and just one (16%) with MA (p < 0.001). LAmB performed better than MA in terms of mean treatment length (7.4 days vs 25.9 days, p < 0.001), time to becoming afebrile (1.7 vs 13.7 days, p < 0.001), and length of hospital stay (10.9 vs 19.4 days, p = 0.001). CONCLUSION: Paediatric VL in Alicante mainly affects children under five. Children aged ≤24 months present with a lower haemoglobin and white blood cell count. Treatment with LAmB reduces treatment length, time to becoming afebrile and length of hospital stay.


Assuntos
Leishmania/isolamento & purificação , Leishmaniose Visceral/epidemiologia , Leishmaniose Visceral/patologia , Adolescente , Anfotericina B/uso terapêutico , Anticorpos Antiprotozoários/sangue , Antiprotozoários/farmacologia , Sangue/parasitologia , Medula Óssea/parasitologia , Criança , Pré-Escolar , Feminino , Humanos , Lactente , Recém-Nascido , Leishmania/imunologia , Leishmaniose Visceral/tratamento farmacológico , Masculino , Meglumina/uso terapêutico , Antimoniato de Meglumina , Compostos Organometálicos/uso terapêutico , Estudos Retrospectivos , Espanha/epidemiologia
13.
Exp Parasitol ; 188: 79-82, 2018 May.
Artigo em Inglês | MEDLINE | ID: mdl-29625099

RESUMO

The primary choice of drugs to treat Leishmaniasis are the pentavalent antimony-based compounds, nevertheless these drugs presented undesirable side effects. However, safe natural compounds could be used in combination with these drugs to enhance their activity. The aim of this study was to evaluate the sinergism of capsaicin and piperine, isolated from Capsicum frutescens and Piper nigrum, respectively, in combination with meglumine antimoniate against Leishmania infantum promastigote and amastigote forms. Each compound was mixed with the standard drug in several percentage mixtures and tested at various concentrations. Capsaicin and piperine in combination with meglumine antimoniate (25% + 75%) showed better anti-leishmanial activity with EC50 = 4.31 ±â€¯0.44 e 7.25 ±â€¯4.84 µg/mL against promastigote and amastigote forms, respectively. The results point that these spice alkaloids are suitable compounds to be administered in combinations with antileishmanial drugs to improve their action.


Assuntos
Alcaloides/farmacologia , Antiprotozoários/farmacologia , Benzodioxóis/farmacologia , Capsaicina/farmacologia , Leishmania infantum/efeitos dos fármacos , Meglumina/farmacologia , Compostos Organometálicos/farmacologia , Piperidinas/farmacologia , Alcamidas Poli-Insaturadas/farmacologia , Alcaloides/uso terapêutico , Antiprotozoários/uso terapêutico , Benzodioxóis/uso terapêutico , Capsaicina/uso terapêutico , Cromatografia Líquida de Alta Pressão , Sinergismo Farmacológico , Concentração Inibidora 50 , Leishmaniose Visceral/tratamento farmacológico , Espectroscopia de Ressonância Magnética , Meglumina/uso terapêutico , Antimoniato de Meglumina , Compostos Organometálicos/uso terapêutico , Piperidinas/uso terapêutico , Alcamidas Poli-Insaturadas/uso terapêutico , Espectrofotometria Ultravioleta
14.
Vet Parasitol ; 254: 135-141, 2018 Apr 30.
Artigo em Inglês | MEDLINE | ID: mdl-29656998

RESUMO

The aim of this study was to evaluate the possible changes in the concentration of anti-Leishmania antibodies in saliva samples from dogs with clinical leishmaniosis after short-term treatment. Twenty dogs with clinical signs and laboratory abnormalities compatible with canine leishmaniosis (CanL) were diagnosed and treated with a standard antimonial plus allopurinol therapy. The concentration of anti-Leishmania IgG2 and IgA antibodies in saliva was measured at the time of diagnosis (day 0) and after treatment (day 30) by time-resolved immunofluorometric assays (TR-IFMAs) and results were compared with those of serum. In addition, correlations between antibody concentrations in saliva and serum, clinical scores and selected laboratory analytes were calculated. TR-IFMA results were expressed as Units of Fluorometry for Leishmania (UFL). Most dogs that adequately responded to treatment (n = 17) showed a reduction of anti-Leishmania antibodies in saliva [median IgG2: from 678.0 (day 0) to 201.1 UFL (day 30), p < 0.0001; median IgA: from 91.3 (day 0) to 60.2 UFL (day 30), p < 0.01] in accordance with clinical improvement (p < 0.0001). However, two of these dogs showed an increase of anti-Leishmania antibodies in saliva. Among dogs that did not improve after one month of treatment (n = 3), two showed a reduction in serum and saliva antibodies. In these two dogs, clinical recovery was achieved after one additional month of treatment with allopurinol. The other dog that did not respond to treatment showed increases in the concentration of anti-Leishmania antibodies, both in saliva and serum, and did not adequately respond to an additional month of treatment with allopurinol. From this pilot study, it could be concluded that, despite the low number of dogs used, the measurement of anti-Leishmania IgG2 and IgA antibodies in saliva could have a potential use for treatment monitoring of CanL, provided that a sufficient amount of specific antibodies is present at diagnosis. This is because, especially in the case of IgG2, there is a high correlation between the saliva and serum concentrations, and the reduction of antibodies is generally in accordance with the clinical improvement. Further long-term studies with a larger population should be undertaken to confirm this potential.


Assuntos
Alopurinol/uso terapêutico , Antiprotozoários/uso terapêutico , Doenças do Cão/prevenção & controle , Leishmania infantum/imunologia , Leishmaniose Visceral/veterinária , Meglumina/uso terapêutico , Compostos Organometálicos/uso terapêutico , Animais , Anticorpos Antiprotozoários/análise , Anticorpos Antiprotozoários/sangue , Anticorpos Antiprotozoários/metabolismo , Cães , Feminino , Leishmaniose Visceral/prevenção & controle , Masculino , Antimoniato de Meglumina , Saliva/parasitologia
15.
J Pharm Pharmacol ; 70(6): 768-777, 2018 Jun.
Artigo em Inglês | MEDLINE | ID: mdl-29532470

RESUMO

OBJECTIVES: To evaluate the analgesic effect of Glucantime (antimoniate N-methylglucamine) in Leishmania amazonensis infection and complete Freund's adjuvant (CFA), chronic paw inflammation model, in BALB/c mice. METHODS: Two models of chronic inflammatory pain in BALB/c mice paw were used: infection with L. amazonensis and CFA stimulation. Both animals models received daily treatment with Glucantime (10 mg/kg, i.p.) and during the treatment was measured the mechanical hyperalgesia with electronic version of von Frey filaments. After the treatment, the paw skin sample was collected for analysis of myeloperoxidase (MPO) and N-acetyl-ß-glucosaminidase (NAG) activity, and IL-1ß, TNF-α, IL-6, IFN-γ and IL-10 cytokines production by ELISA. KEY FINDINGS: Leishmania amazonensis-induced chronic inflammation with significant increase in mechanical hyperalgesia, MPO and NAG activity, and IL-1ß, TNF-α and IL-6 production in the paw skin. Glucantime (10 mg/kg, i.p.) inhibited L. amazonensis-induced mechanical hyperalgesia and IL-1ß and IL-6 cytokines productions. In chronic inflammatory model induced by CFA, Glucantime treatment during 7 days inhibited CFA-induced mechanical hyperalgesia, MPO and NAG activity, and IL-1ß, TNF-α, IL-6 and IFN-γ production as well as increased IL-10 production. CONCLUSIONS: Our data demonstrated that Glucantime reduced the chronic inflammatory pain induced by L. amazonensis and CFA stimuli by inhibiting the hyperalgesic cytokines production.


Assuntos
Dor Crônica/tratamento farmacológico , Inflamação/tratamento farmacológico , Leishmaniose Cutânea/tratamento farmacológico , Meglumina/uso terapêutico , Compostos Organometálicos/uso terapêutico , Acetilglucosaminidase/metabolismo , Animais , Dor Crônica/complicações , Citocinas/metabolismo , Adjuvante de Freund , Inflamação/induzido quimicamente , Inflamação/complicações , Masculino , Antimoniato de Meglumina , Camundongos , Peroxidase/metabolismo , Pele/metabolismo
16.
Korean J Parasitol ; 56(1): 21-24, 2018 Feb.
Artigo em Inglês | MEDLINE | ID: mdl-29529846

RESUMO

Cutaneous leishmaniasis (CL) can be seen in 2 forms, zoonotic and anthroponotic, in Iran. In this study, epidemiological aspects of CL were studied during an 8-year period (2009-2016) in city of Kashan, central Iran. The demographic and epidemiological data, including age, sex, occupation, number and site of the lesions, treatment regimen, past history of CL, and season of all patients were gathered from the health centers. Descriptive statistics were used to describe features of the study data. Total 2,676 people with CL were identified. The highest annual incidence was estimated to be 182 per 100,000 population in 2009 and the least was in 2016 (47 per 100,000 population). The highest frequency affected age groups were observed in 20-29 year-old patients (20.9%). More than 51% of the patients were under 30 years old. The maximum frequency of the disease, 1,134 (43.3%), was seen in autumn. The most common location of lesions was hands (61.4%). Most of the patients (81.6%) were treated by systemic glucantime regimen. In the city of Kashan, the incidence rate of the CL disease is significantly higher than many other regions of Iran. To reduce the risk of disease, control of reservoir hosts and vectors of disease, and education of individual protection are strongly recommended.


Assuntos
Leishmaniose Cutânea/epidemiologia , Adolescente , Adulto , Fatores Etários , Animais , Criança , Pré-Escolar , Reservatórios de Doenças , Vetores de Doenças , Feminino , Educação em Saúde , Humanos , Incidência , Lactente , Irã (Geográfico)/epidemiologia , Leishmania tropica , Leishmaniose Cutânea/tratamento farmacológico , Leishmaniose Cutânea/parasitologia , Leishmaniose Cutânea/prevenção & controle , Masculino , Meglumina/uso terapêutico , Antimoniato de Meglumina , Pessoa de Meia-Idade , Compostos Organometálicos/uso terapêutico , Estações do Ano , Fatores de Tempo , Adulto Jovem
17.
Vet Immunol Immunopathol ; 198: 65-69, 2018 Apr.
Artigo em Inglês | MEDLINE | ID: mdl-29571520

RESUMO

The aim of this study was to evaluate the changes in anti-Leishmania IgG2 and IgA antibodies measured by two time-resolved immunofluorometric assays (TR-IFMAs) recently validated and by means of a commercially available ELISA test in dogs with leishmaniosis after treatment. Serum samples from 16 dogs with clinical leishmaniosis were obtained on days 0, 30 and 180 of treatment. In addition, these serological changes were compared with the clinical signs and selected analytes (total proteins, albumin, globulins and urinary protein:creatinine ratio). Concentrations of IgG2 and IgA by TR-IFMA were significantly lower on days 30 (p < 0.05) and 180 of treatment (p < 0.0001) compared to day 0 in dogs that showed a positive response to treatment. Magnitudes of decrease of IgG2 (1.66 and 20.4-fold) and IgA (1.3 and 11.43-fold) concentrations on days 30 and 180 were greater than those of the commercially available ELISA test (1.29 and 2.06-fold), and that of other analytes (total proteins: 1.11 and 1.25-fold; globulins: 1.22 and 1.74-fold; and albumin: 0.93 and 0.8-fold). This study shows that serum IgG2 and IgA anti-Leishmania antibodies measured by TR-IFMAs were useful for treatment monitoring in dogs with leishmaniosis, showing a significant reduction in antibody concentrations earlier than the commercial ELISA assay. Results suggest that the method used for antibody measurements greatly influences the results and, consequently, the usefulness for measuring anti-Leishmania antibodies to monitor the treatment of canine leishmaniosis.


Assuntos
Anticorpos Antiprotozoários/sangue , Doenças do Cão/parasitologia , Fluorimunoensaio/veterinária , Leishmaniose/veterinária , Alopurinol/uso terapêutico , Animais , Anticorpos Antiprotozoários/imunologia , Antiprotozoários/uso terapêutico , Doenças do Cão/tratamento farmacológico , Doenças do Cão/imunologia , Cães , Ensaio de Imunoadsorção Enzimática/veterinária , Imunoglobulina A/sangue , Imunoglobulina A/imunologia , Imunoglobulina G/sangue , Imunoglobulina G/imunologia , Leishmaniose/sangue , Leishmaniose/tratamento farmacológico , Leishmaniose/imunologia , Meglumina/uso terapêutico , Antimoniato de Meglumina , Compostos Organometálicos/uso terapêutico , Resultado do Tratamento
18.
Acta Pharmacol Sin ; 39(8): 1259-1272, 2018 Aug.
Artigo em Inglês | MEDLINE | ID: mdl-29542683

RESUMO

Diterpene ginkgolides meglumine injection (DGMI) is a therapeutic extract of Ginkgo biloba L, which has been used for the treatment of cerebral ischemic stroke in China. Ginkgolides A, B and C are the main components of DGMI. This study was designed to investigate the neuroprotective effects of DGMI components against ischemic stroke in vivo and in vitro. Acute cerebral ischemic injury was induced in rats by occlusion of the middle cerebral artery (MCA) for 1.5 h followed by 24 h reperfusion. The rats were treated with DGMI (1, 3 and 10 mg/kg, iv) at the onset of reperfusion and 12 h after reperfusion. Administration of DGMI significantly decreased rat neurological deficit scores, reduced brain infarct volume, and induced protein kinase B (Akt) phosphorylation, which prompted the nuclear translocation of nuclear factor-erythroid 2-related factor 2 (Nrf2) and phosphorylation of the survival regulatory protein cyclic AMP-responsive element binding protein (CREB). Nrf2 activation led to expression of the downstream protein heme oxygenase-1 (HO-1). In addition, PC12 cells were subjected to oxygen-glucose deprivation/reperfusion (OGD/R) in vitro, treatment with DGMI (1, 10 and 20 µg/mL) or ginkgolides A, B or C (10 µmol/L for each) significantly reduced PC12 cell death and increased phosphorylation of Akt, nuclear translocation of Nrf2 and activation of CREB. Activation of Nrf2 and CREB could be reversed by co-treatment with a phosphoinositide-3-kinase (PI3K) inhibitor LY294002. These observations suggest that ginkgolides act as novel extrinsic regulators activating both Akt/Nrf2 and Akt/CREB signaling pathways, protecting against cerebral ischemia/reperfusion (I/R) damage in vivo and in vitro.


Assuntos
Ginkgolídeos/uso terapêutico , Infarto da Artéria Cerebral Média/prevenção & controle , Fármacos Neuroprotetores/uso terapêutico , Traumatismo por Reperfusão/prevenção & controle , Transdução de Sinais/efeitos dos fármacos , Animais , Edema Encefálico/prevenção & controle , Proteína de Ligação ao Elemento de Resposta ao AMP Cíclico/metabolismo , Ginkgo biloba/química , Ginkgolídeos/farmacologia , Heme Oxigenase (Desciclizante)/metabolismo , Masculino , Meglumina/farmacologia , Meglumina/uso terapêutico , Fator 2 Relacionado a NF-E2/metabolismo , Fármacos Neuroprotetores/farmacologia , Células PC12 , Proteínas Proto-Oncogênicas c-akt/metabolismo , Ratos , Ratos Sprague-Dawley
20.
Vet Res Commun ; 42(2): 121-130, 2018 Jun.
Artigo em Inglês | MEDLINE | ID: mdl-29453596

RESUMO

The use of natural products is a promising approach for treating visceral leishmaniosis. (-)-α-Bisabolol is a sesquiterpene that have been proved active in vivo on Leishmania infantum-infected mice without showing toxicity. A single-centre, parallel-group, randomized, exploratory study was designed to assess its efficacy in a canine leishmaniosis model involving naturally infected dogs. In this clinical trial, 12 dogs were allocated into two groups and were treated with either meglumine antimoniate (100 mg/kg) through subcutaneous route or (-)-α-bisabolol (30 mg/kg) through oral route for two treatment series of 30 days, separated by a 30-day interval. A 4-month follow-up period was established as well. Parasite loads in bone marrow, lymph node and blood were estimated through quantitative PCR. Antibody titres were determined through immunofluorescence antibody test and cytokine expression values were estimated through real-time reverse transcription-PCR. Treatment safety was assessed through the evaluation of weight, gastrointestinal alterations and hematological and biochemical parameters in blood. Analyses were performed before and after treatment, and after a 4-months follow-up period. Treatment with the sesquiterpene was effective at decreasing parasite loads and increasing gamma-interferon expression level. Dogs treated with (-)-α-bisabolol did not show any toxicity sign. These results were better than those obtained using the reference drug, meglumine antimoniate. The natural compound seemed to induce a Th1 immune response that led to parasitological and clinical improvement without showing any safety issue, suggesting a high potential for the treatment of canine and human visceral leishmaniosis.


Assuntos
Antiprotozoários/uso terapêutico , Doenças do Cão/tratamento farmacológico , Leishmaniose Visceral/veterinária , Sesquiterpenos/uso terapêutico , Animais , Anticorpos Antiprotozoários/sangue , Cães , Leishmaniose Visceral/tratamento farmacológico , Meglumina/administração & dosagem , Meglumina/uso terapêutico , Antimoniato de Meglumina , Sesquiterpenos Monocíclicos , Compostos Organometálicos/administração & dosagem , Compostos Organometálicos/uso terapêutico , Carga Parasitária , Sesquiterpenos/administração & dosagem , Resultado do Tratamento
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...